丰白散治疗慢性阻塞性肺疾病稳定期气阴两虚证的临床观察  

Clinical Observation of the Treatment of Fengbaisan (丰白散) on Qi and Yin Deficiency Syndrome in Chronic Obstructive Pulmonary Disease at Stable Stage

作　　者：王煜[1] 苏南湘[2] 潘三改[3] WANG Yu;SU Nan-xiang;PAN San-gai(Xiangya Hospital,Central South University,Changsha Hu＇nan 410008,China;The 2nd Xiangya Hospital,Central South University,Changsha Hu＇nan 410011,China;Tianfin First Aid Center,Tianfin 300160,China)

机构地区：[1]中南大学湘雅医院,湖南长沙410008 [2]中南大学湘雅二医院,湖南长沙410011 [3]天津市急救中心,天津300160

出　　处：《中医药导报》2018年第17期90-93,共4页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：湖南省科技厅计划项目(2011SK3232);湖南省中医药管理局科研项目(201194)

摘　　要：目的:探讨丰白散对慢性阻塞性肺疾病(COPD)稳定期气阴两虚证的临床疗效。方法:将92例COPD稳定期气阴两虚证患者随机分为对照组(46例)和治疗组(46例)。两组均予常规治疗,对照组在此基础上予沙美特罗替卡松粉吸入剂(舒利迭)吸入治疗,治疗组在对照组基础上加服丰白散,疗程均为3个月。比较两组患者治疗前后6 min步行试验(6MWT)、呼吸困难评分、肺功能指标(最大通气量(MVV)、第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、第一秒用力呼气容积/用力肺活量(FEV1/FVC)),观察两组临床疗效和不良反应发生情况。结果:治疗后,两组患者的6MWT、肺功能指标(MVV、FEV1、FVC、FEV1/FVC)较治疗前均有明显改善(P<0.05),且治疗组改善效果优于对照组(P<0.01);两组患者的呼吸困难评分较治疗前均有下降(P<0.05),治疗组明显低于对照组(P<0.01)。治疗组临床总有效率为93.48%,明显高于对照组的80.43%,组间差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:COPD稳定期气阴两虚证患者配合中药丰白散治疗,能有效改善肺功能,缓解临床症状,且不增加药物不良反应的发生率,具备一定的安全性。Objective： To stduy the clinical efficacy of Fengbaisan on the treatment of Qi and Yin deficiency syndrome in chronic obstructive pulmonary disease（COPD） at stable stage. Methods： A total of 96 patients of COPD at stable stage with syndrome of Qi and Yin deficiency were randomly divided into control group（n =46） and observation group（n =46）. The control group was given inspiration of salmeterol fluticasone besides the conventional therapy, while the observation group was additionally treated with oral Fengbaisan. The treatment period was 3 months. The 6-minute walk test（6 MWT）, m MRC score and indexes of pulmonary function（including maximum ventilatory volume（MVV）, forced expiratory volume in one second（FEV1）, forced vital capacity（FVC） and FEV1/FVC） were compared between two groups before and after treatment. The clinical herapeutic effects and the adverse drug reaction in two groups were observed. Results： After treatment, the6 MWT and indexes of pulmonary function（MVV, FEV1, FVC and FEV1/FVC） in two groups were remarkably improved compared with those before treatment（P〈0.05）, and the observation group was superior to the control group（P〈0.01）. The m MRC score of two groups were decreased compared with that before treatment（P〈0.05）,and the observation group was significantly lower than that of the control group（P〈0.01）. The total clinical effective rate in observation group was 93.48%, which was obviously higher than 80.43% in control group（P〈0.05）. There was no significant difference in incidence of adverse drug reaction between two groups（P〈0.05）.Conclusion： Treating patients with Qi and Yin deficiency syndrome in stable COPD with Fengbaisan can effectively improve the pulmonary function and relieve the clinical symptom. It does not increase the incidence of adverse drug reactions, and has certain safety.

关 键 词：丰白散 慢性阻塞性肺疾病 气阴两虚证 稳定期 

分 类 号：R256.1[医药卫生—中医内科学]